Abstract
inhibitors of proteases are currently emerging as a potential anti-cancer modality. nonselective protease inhibitors are cytotoxic to leukemia and cancer cell lines and we found that this cytotoxicity is correlated with their potency as inhibitors of the proteasome but not as inhibitors of calpain and cathepsin. highly selective inhibitors of the proteasome were more cytotoxic and fast-acting than less selective inhibitors (ps341>>alln>>allm). induction of wt p53 correlated with inhibition of the proteasome and antiproliferative effect in mcf-7, a breast cancer cell line, which was resistant to apoptosis caused by proteasome inhibitors. in contrast, inhibitors of the proteasome induced apoptosis in four leukemia cell lines lacking wt p53. the order of sensitivity of leukemia cells was: jurkat>hl60⩾u937>>K562. The highly selective proteasome inhibitor PS-341 induced cell death with an IC50 as low as 5 nM in apoptosis-prone leukemia cells. Cell death was preceded by p21WAF1/CIP1 accumulation, an alternative marker of proteasome inhibition, and by cleavage of PARP and Rb proteins and nuclear fragmentation. Inhibition of caspases abrogated PARP cleavage and nuclear fragmentation and delayed, but did not completely prevent cell death caused by PS-341. Reintroduction of wt p53 into p53-null PC3 prostate carcinoma cells did not increase their sensitivity to proteasome inhibitors. Likewise, comparison of parental and p21-deficient cells demonstrated that p21WAF1/CIP1 was dispensable for proteasome inhibitor-induced cytotoxicity. We conclude that accumulation of wt p53 and induction of apoptosis are independent markers of proteasome inhibition.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fisher DE . Apoptosis in cancer therapy: crossing the threshold Cell 1994 78: 539–542
Kastan MB, Canman CE, Leonard CJ . P53, cell cycle control and apoptosis: implications for cancer Cancer Metastasis Rev 1995 14: 3–15
Martin SJ, Green DR . Apoptosis as a goal of cancer therapy Curr Opin Oncol 1994 6: 616–621
Hannun YA . Apoptosis and the dilemma of cancer chemotherapy Blood 1997 89: 1845–1853
Samali A, Zhivotovsky B, Jones D, Nagata S, Orrenius S . Apoptosis: cell death defined by caspase activation Cell Death Differ 1999 6: 495–496
Lin KI, Baraban JM, Ratan RR . Inhibition versus induction of apoptosis by proteasome inhibitors depends on concentration Cell Death Differ 1998 5: 577–583
Piedimonte G, Crinelli R, Salda LD, Corsi D, Pennisi MG, Kramer L, Casabianca A, Sarli G, Bendinelli M, Marcato PS, Magnani M . Protein degradation and apoptotic death in lymphocytes during Fiv infection: activation of the ubiquitin-proteasome proteolytic system Exp Cell Res 1999 248: 381–390
Deiss LP, Galinka H, Berissi H, Cohen O, Kimchi A . Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha EMBO J 1996 15: 3861–3870
Squier MK, Sehnert AJ, Sellins KS, Malkinson AM, Takano E, Cohen JJ . Calpain and calpastatin regulate neutrophil apoptosis J Cell Physiol 1999 178: 311–319
Villa PG, Henzel WJ, Sensenbrenner M, Henderson CE, Pettmann B . Calpain inhibitors, but not caspase inhibitors, prevent actin proteolysis and DNA fragmentation during apoptosis J Cell Sci 1998 111: 713–722
Waterhouse NJ, Finucane DM, Green DR, Elce JS, Kumar S, Alnemri ES, Litwack G, Khanna K, Lavin MF, Watters DJ . Calpain activation is upstream of caspases in radiation-induced apoptosis Cell Death Differ 1998 5: 1051–1061
Wood DE, Newcomb EW . Caspase-dependent activation of calpain during drug-induced apoptosis J Biol Chem 1999 274: 8309–8315
Wu GS, Saftig P, Peters C, El-Deiry WS . Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity Oncogene 1998 16: 2177–2183
Grassilli E, Benatti F, Dansi P, Giammarioli AM, Malorni W, Franceschi C, Desiderio MA . Inhibition of proteasome function prevents thymocyte apoptosis: involvement of ornithine decarboxylase Biochem Biophys Res Commun 1998 250: 293–297
Shinohara K, Tomioka M, Nakano H, Tone S, Ito H, Kawashima S . Apoptosis induction resulting from proteasome inhibition Biochem J 1996 317: 385–388
Lopes UG, Erhardt P, Yao R, Cooper GM . p53-dependent induction of apoptosis by proteasome inhibitors J Biol Chem 1997 272: 12893–12896
Drexler HC . Activation of the cell death program by inhibition of proteasome function Proc Natl Acad Sci USA 1997 94: 855–860
An B, Goldfarb RH, Siman R, Dou QP . Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts Cell Death Differ 1998 5: 1062–1075
Chandra J, Niemer I, Gilbreath J, Kliche KO, Andreeff M, Freireich EJ, Keating M, McConkey DJ . Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes Blood 1998 92: 4220–4229
Orlowski RZ . The role of the ubiquitin-proteasome pathway in apoptosis Cell Death Differ 1999 6: 303–313
Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ . Proteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res 1999 59: 2615–2622
Fenteany G, Schreiber SL . Lactacystin, proteasome function, and cell fate J Biol Chem 1998 273: 8545–8548
Zhang XM, Lin H, Chen C, Chen BD . Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells Biochem J 1999 340: 127–133
Wagenknecht B, Hermisson M, Eitel K, Weller M . Proteasome inhibitors induce p53/p21-independent apoptosis in humanglioma cells Cell Physiol Biochem 1999 9: 117–125
Gottlieb TM, Oren M . p53 and apoptosis Semin Cancer Biol 1998 8: 359–368
Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, Seth P . Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27 Cancer Res 1997 57: 5441–5445
Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, Haber DA . Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1 Cell 1999 97: 575–586
Ciechanover A . The ubiquitin-proteasome proteolytic pathway Cell 1994 79: 13–21
Alessandrini A, Chiaur DS, Pagano M . Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation Leukemia 1997 11: 342–345
Blagosklonny MV, An WG, Melillo G, Nguyen P, Trepel J, Neckers L . Regulation of BRCA1 by protein degradation Oncogene 1999 18: 6460–6468
Maki CG, Huibregtse JM, Howley PM . In vivo ubiquitination and proteasome-mediated degradation of p53 Cancer Res 1996 56: 2649–2654
Blagosklonny MV, Wu GS, Omura S, El-Deiry WS . Proteasome-dependent regulation of p21WAF1/CIP1 expression Biochem Biophys Res Commun 1996 227: 564–569
Dietrich C, Bartsch T, Schanz F, Oesch F, Wieser RJ . p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblast Proc Natl Acad Sci USA 1996 93: 10815–10819
Kubbutat MH, Vousden KH . Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability Mol Cell Biol 1997 17: 460–468
Gonen H, Shkedy D, Barnoy S, Kosower NS, Ciechanover A . On the involvement of calpains in the degradation of the tumor suppressor protein p53 FEBS Lett 1997 406: 17–22
Salvat C, Aquaviva C, Jariel-Encontre I, Ferrara P, Pariat M, Steff AM, Carillo S, Piechaczyk M . Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo? Mol Biol Rep 1999 26: 45–51
Waldman T, Kinzler KW, Vogelstein B . p21 is necessary for the p53-mediated G1 arrest in human cancer cells Cancer Res 1995 55: 5187–5190
Blagosklonny MV, Somasundaram K, Wu GS, El-Deiry WS . Wild-type p53 is not sufficient for serum starvation-induced apoptosis in cancer cells but accelerates apoptosis in sensitive cells Int J Oncol 1997 11: 1165–1170
Blagosklonny MV, Chuman Y, Bergan RC, Fojo T . Mitogen activated protein kinase pathways is dispensible for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells Leukemia 1999 13: 1028–1036
Blagosklonny MV . Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal Leukemia 1999 13: 2031–2035
Choi YH, Lee SJ, Nguyen P, Jang JS, Lee J, Wu ML, Takano E, Maki M, Henkart PA, Trepel JB . Regulation of cyclin D1 by calpain protease J Biol Chem 1997 272: 28479–28484
Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Coldberg AL . Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules Cell 1994 78: 761–771
Wang KK, Nath R, Posner A, Raser KJ, Buroker-Kilgore M, Hajimohammadreza I, Probert AW Jr, Marcoux FW, Ye Q, Takano E, Hatanaka M, Maki M, Caner H, Collins JL, Fergus A, Lee KS, Lunney EA, Hays SJ, Yuen P . An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective Proc Natl Acad Sci USA 1996 93: 6687–6692
Whitesell L, Sutphin P, An WG, Schulte T, Blagosklonny MV, Neckers L . Geldanamycin-stimulated destabolization of mutated p53 is mediated by the proteasome in vivo Oncogene 1997 14: 2809–2816
Pan Y, Haines DS . The pathway regulating MDM2 protein degradation can be altered in human leukemic cells Cancer Res 1999 59: 2064–2067
Laumann R, Jucker M, Tesch H . Point mutations in the conserved regions of the p53 tumor suppressor gene do not account for the transforming process in the Jurkat acute lymphoblastic leukemia T cells Leukemia 1992 6: 227–228
Bhalla K, Ibrado AM, Tourkina E, Tang C, Maloney ME, Huang Y . Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells Leukemia 1993 7: 563–568
Bullock G, Ray S, Reed JC, Krajewski S, Ibrado AM, Huang Y, Bhalla K . Intracellular metabolism of Ara-C and resulting DNA fragmentation and apoptosis of human AML HL-60 cells possessing disparate levels of Bcl-2 protein Leukemia 1996 10: 1731–1740
McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TM . Bcr-Abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death Blood 1994 83: 1179–1187
Martins LM, Mesner PW, Kottke TJ, Basi GS, Sinha S, Tung JS, Svingen PA, Madden BJ, Takahashi A, McCormick DJ, Earnshaw WC, Kaufmann SH . Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis Blood 1997 90: 4283–4296
Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E . BCR-ABL delays apoptosis upstream of procaspase-3 activation Blood 1998 91: 2415–2422
Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K . Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3 Blood 1998 91: 1700–1705
Blagosklonny MV, El-Deiry WS . In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug Int J Cancer 1996 67: 386–392
Katayose D, Gudas J, Nguyen H, Srivastava S, Cowan KH, Seth P . Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells Clin Cancer Res 1995 1: 889–897
Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B . Genetic determinants of p53-induced apoptosis and growth arrest Genes Dev 1996 10: 1945–1952
Herrmann JL, Briones FJ, Brisbay S, Logothetis CJ, McDonnell TJ . Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53 Oncogene 1998 17: 2889–2899
Freemerman AJ, Vrana JA, Tombes RM, Jiang H, Chellappan SP, Fisher PB, Grant S . Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation in human myeloid leukemia cells (HL-60) Leukemia 1997 11: 504–513
Glockzin S, von Knethen A, Scheffner M, Brne B . Activation of the cell death program by nitric oxide involves inhibition of the proteasome J Biol Chem 1999 274: 19581–19586
Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M . Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27 Science 1995 269: 682–685
Urano T, Yashiroda H, Muraoka M, Tanaka K, Hosoi T, Inoue S, Ouchi Y, Toyoshima H . p57(Kip2) is degraded through the proteasome in osteoblasts stimulated to proliferation by transforming growth factor betal J Biol Chem 1999 274: 12197–12200
Antoku K, Liu Z, Johnson DE . Inhibition of caspase proteases by CrmA enhances the resistance of human leukemic cells to multiple chemotherapeutic agents Leukemia 1997 11: 1665–1672
Classen CF, Fulda S, Friesen C, Debatin KM . Decreased sensitivity of drug-resistant cells towards T cell cytotoxicity Leukemia 1999 13: 410–418
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
An, W., Hwang, SG., Trepel, J. et al. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 14, 1276–1283 (2000). https://doi.org/10.1038/sj.leu.2401812
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401812
Keywords
This article is cited by
-
Production Enhancement of an Anticoagulant Trypsin Inhibitor from Oceanimonas sp. BPMS22 and Its Anti-cancer Activity
International Journal of Peptide Research and Therapeutics (2021)
-
Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells
Journal of Experimental & Clinical Cancer Research (2017)
-
The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Blood Cancer Journal (2017)
-
A Bowman–Birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibition
Cell Death Discovery (2016)
-
Polyphenols act synergistically with doxorubicin and etoposide in leukaemia cell lines
Cell Death Discovery (2015)